Drug Profile
Clozapine modified-release - Intas Pharmaceuticals
Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Intas Pharmaceuticals
- Class Antipsychotics; Dibenzazepines
- Mechanism of Action Alpha adrenergic receptor antagonists; Dopamine D2 receptor antagonists; Muscarinic receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Schizophrenia in India (PO, Controlled release)
- 30 Jan 2020 Intas Pharmaceutical plans a phase I trial in Schizophrenia in India (PO) (CTRI2019-12-022239)
- 29 Jan 2020 Intas Pharmaceuticals plans a clinical trial for Schizophrenia (Treatment-resistant) in India (PO, Controlled release, Once daily), in February 2020 (CTRI2019-10-021798)